By: Our Staff Reporter
Addis Ababa (Ethiopia Today), July 14, 2026: MIDROC Investment Group has officially launched seven types of pediatric intravenous (IV) fluid medicines today. Prepared in 100ml packages, these glucose-based treatments are designed to fill a critical clinical gap in healthcare facilities while saving valuable foreign currency for the nation.
Speaking at the launch event, State Minister of Health, Frehiwot Abebe, recalled that just three years ago, Ethiopia’s domestic medicine manufacturing capacity was at a mere 8 percent. Today, she revealed that the country has successfully scaled up to produce 44 percent of its required medicines domestically.
State Minister Frehiwot emphasized that this rapid growth reflects the government’s strong commitment to the healthcare sector. She noted that increasing domestic production builds essential capacity, allowing Ethiopia to break free from import dependency and achieve self-sufficiency in medicines and medical supplies.
Solomon Gebreamanuel, General Manager of Pharmacure under MIDROC Investment Group, highlighted that local production of these pediatric fluids will significantly reduce the foreign exchange previously spent on imports. Furthermore, he explained that securing a domestic supply ensures essential medicines remain easily and timely accessible, even during global supply chain disruptions.

The launch event also underscored the wider socio-economic benefits of establishing local pharmaceutical factories. Officials pointed out that these domestic plants are highly instrumental in creating extensive job opportunities for citizens and facilitating critical technology and knowledge transfer within the country.